Is Minerva Neurosciences, Inc. overvalued or undervalued?

As of 2 August 2021, Minerva Neurosciences, Inc. has moved from a valuation grade of very attractive to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued. Key ratios include a P/E ratio of 2.06, an EV to EBIT of -2.91, and a PEG ratio of 0.02, which suggest poor profitability and growth prospects.
In comparison to its peers, Veru, Inc. has a P/E of -2.30 and an EV to EBITDA of -1.71, while Outlook Therapeutics, Inc. has a P/E of -0.95 and an EV to EBITDA of -1.28, both indicating challenges in their respective valuations. The negative return of Minerva Neurosciences compared to the S&P 500, particularly a YTD decline of -20.33% versus a gain of 2.44% for the index, further reinforces the notion of overvaluation amidst its deteriorating financial health.